ATOS - Company ID 0001488039
The table below shows ATOSSA THERAPEUTICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.58M | -$5.96M | -$4.70M | -$7.02M | -$4.88M | -$4.41M |
| Capital expenditure | $0.00 | $9.00K | $6.00K | $0.00 | $13.00K | $0.00 |
| Investing cash flow | $0.00 | -$9.00K | -$6.00K | $0.00 | -$13.00K | $0.00 |
| Dividends paid | - | - | - | - |
ATOSSA THERAPEUTICS, INC. reported operating cash flow of -$29.76M for fiscal year 2025. That is down 41.5% from -$21.03M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.37M (FY 2016) to -$29.76M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | $0.00 | $204.00K | $0.00 | $0.00 | $102.43M |